149606-47-3

Upstream product

• 1053701-87-3 (3R,4S)-4-(Benzyloxycarbonyl-methyl-amino)-3-methoxy-5-methyl-hexanoic acid 
• 115-11-7 isobutene 
• 1611479-63-0 (3R,4S)-tert-butyl 4-((benzyloxycarbonyl)(methyl)amino)-3-hydroxy-5-methylhexanoate 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 202806-77-7 t-butyl-(3R,4S)-4-(N-benzyloxycarbonylamino)-3-hydroxy-5-methyl-hexanoate 
• 333-27-7 methyl trifluoromethanesulfonate 
• 149632-88-2 (3R,4S)-4-(Benzyloxycarbonyl-methyl-amino)-3-methoxy-5-methyl-hexanoic acid methyl ester 

Downstream Products

• 1611479-81-2 (2R,3R)-1-(tert-butyldiphenylsilyloxy)-3-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)propan-2-yl 3-((S)-1-((3R,4S)-4-((S)-2-((2S,3S)-2-(dimethylamino)-3-methylpentanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylhexanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoate 
• 149606-52-0 (3R,4S)-tert-butyl 4-((S)-2-(benzyloxycarbonylamino)-N,3-dimethylbutanamido)-3-methoxy-5-methylhexanoate 

Relevant academic research and scientific papers

Total synthesis and cytotoxicity of the marine natural product malevamide D and a photoreactive analog

The marine natural product malevamide D from the cyanobacterium Symploca hydnoides was synthesized for the first time. The final peptide coupling linked the dolaisoleuine and dolaproine subunits. The phenyl group of malevamide D was also functionalized wi

Tetrapeptides as antitumor agents

The present invention provides anti-tumor peptides of Formula I, and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N,N-dimethyl-2-ethylphenylglycyl, or an amino ac

Pentapeptides as antitumor agents

The present invention provides anti-tumor peptides of Formula I, and the acid salts thereof. A is an amino acid residue of the formula (CH3)2 N--CHX--CO, wherein X is a normal or branched alkyl group. B is an amino acid residue s

Synthesis and antitumor activity of novel dolastatin 10 analogs

Dolastatin 10 (1) is a potent antineoplastic pentapeptide. Novel dolastatin 10 analogs each modified at one of the constituent amino acid derivatives, were synthesized and their antitumor activity was evaluated against P388 leukemia in mice. The structural requirements for antitumor activity are discussed. Some of the analogs, 31c, 35c, 38b, and 50c showed excellent activity in vivo. Highly active 50c, which lacks the thiazole group of 1, was selected for further development as an antitumor agent.